Correction: Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy (PLoS ONE (2014) 9: 11 (e111079) DOI: 10.1371/journal.pone.0111079);Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Cao, Limin ^a   Han, Gang ^a   Gu, Ben ^a   Yin, Hai Fang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; C3H MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; FEASIBILITY STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; MOUSE; MOUSE STRAIN; NONHUMAN; SENSITIVITY ANALYSIS; STRAIN DIFFERENCE; TREATMENT RESPONSE; WILD TYPE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ALTERNATIVE RNA SPLICING; ANIMAL; C57BL MOUSE; DISEASE MODEL; DNA SEQUENCE; EXON; GENE THERAPY; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; MUSCULAR DYSTROPHY, DUCHENNE;

ALTERNATIVE SPLICING; ANIMALS; DISEASE MODELS, ANIMAL; DYSTROPHIN; EXONS; GENETIC THERAPY; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; SEQUENCE ANALYSIS, DNA;

EID: 84909641181     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0207817     Document Type: Erratum

References (42)

1. Hoffman EP, Knudson CM, Campbell KP, Kunkel LM (1987) Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature 330: 754-758.
2. Angelini C, Peterle E (2012) Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol 31: 9-15.
3. Bhattacharya S, Nayak A, Schiavone M, K Bhattacharya S (2004) Solubilization and concentration of carbon dioxide: novel spray reactors with immobilized carbonic anhydrase. Biotechnol Bioeng 86: 37-46.
4. Tidball JG, Wehling-Henricks M (2004) Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events. Pediatr Res 56: 831-841.
5. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
6. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
7. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
8. Goyenvalle A, Seto JT, Davies KE, Chamberlain J (2011) Therapeutic approaches to muscular dystrophy. Hum Mol Genet 20: R69-78.
9. Extance A (2009) Targeting RNA: an emerging hope for treating muscular dystrophy. Nat Rev Drug Discov 8: 917-918.
10. Ahmad A, Brinson M, Hodges BL, Chamberlain JS, Amalfitano A (2000) Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy. Hum Mol Genet 9: 2507-2515.
11. Allamand V, Campbell KP (2000) Animal models for muscular dystrophy: valuable tools for the development of therapies. Hum Mol Genet 9: 2459-2467.
12. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, et al. (2001) Antisenseinduced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 98: 42-47.
13. Wu B, Lu P, Cloer C, Shaban M, Grewal S, et al. (2012) Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am J Pathol 181: 392-400.
14. Rafael JA, Townsend ER, Squire SE, Potter AC, Chamberlain JS, et al. (2000) Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. Hum Mol Genet 9: 1357-1367.
15. Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, et al. (1992) An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13: 115-121.
16. Howell JM, Fletcher S, Kakulas BA, O'Hara M, Lochmuller H, et al. (1997) Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. Neuromuscul Disord 7: 325-328.
17. Klymiuk N, Blutke A, Graf A, Krause S, Burkhardt K, et al. (2013) Dystrophindeficient pigs provide new insights into the hierarchy of physiological derangenments of dystrophic muscle. Hum Mol Genet 22(21): 4368-82.
18. Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, Kaman WE, Janson AA, et al. (2004) Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 10: 232-240.
19. Araki E, Nakamura K, Nakao K, Kameya S, Kobayashi O, et al. (1997) Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. Biochem Biophys Res Commun 238: 492-497.
20. Im WB, Phelps SF, Copen EH, Adams EG, Slightom JL, et al. (1996) Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet 5: 1149-1153.
21. Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, et al. (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18: 1995-2005.
22. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A (2008) Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 31: 1-19.
23. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
24. Wang Q, Yin H, Camelliti P, Betts C, Moulton H, et al. (2010) In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J Gene Med 12: 354-364.
25. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, et al. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177.
26. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, et al. (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9: 1009-1014.
27. Yin H, Betts C, Saleh AF, Ivanova GD, Lee H, et al. (2010) Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther 18: 819-827.
28. Yin H, Lu Q, Wood M (2008) Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 16: 38-45.
29. Islamian JP, Mohammadi M, Baradaran B (2014) Inhibition of human esophageal squamous cell carcinomas by targeted silencing of tumor enhancer genes: an overview. Cancer Biol Med 11: 78-85.
30. Zheng H, Liu JY, Song FJ, Chen KX (2013) Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med 10: 123-130.
31. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, et al. (2009) In vivo comparison of 29-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11: 257-266.
32. Kendall GC, Mokhonova EI, Moran M, Sejbuk NE, Wang DW, et al. (2012) Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Sci Transl Med 4: 164ra160.
33. Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, et al. (2001) Pharmacokinetic properties of 29-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296: 890-897.
34. Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, et al. (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18: 4405-4414.
35. Yang L, Niu H, Gao X, Wang Q, Han G, et al. (2013) Effective exon skipping and dystrophin restoration by 29-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice. PLoS One 8: e61584.
36. Kang JK, Malerba A, Popplewell L, Foster K, Dickson G (2011) Antisenseinduced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Mol Ther 19: 159-164.
37. Goyenvalle A, Davies KE (2011) Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy. Skelet Muscle 1: 8.
38. Malerba A, Sharp PS, Graham IR, Arechavala-Gomeza V, Foster K, et al. (2011) Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther 19: 345-354.
39. Yin H, Saleh AF, Betts C, Camelliti P, Seow Y, et al. (2011) Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 19: 1295-1303.
40. Moulton HM, Moulton JD (2010) Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 1798: 2296-2303.
41. Heemskerk H, de Winter C, van Kuik P, Heuvelmans N, Sabatelli P, et al. (2010) Preclinical PK and PD studies on 29-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther 18: 1210-1217.
42. Crisp A, Yin H, Goyenvalle A, Betts C, Moulton HM, et al. (2011) Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet 20: 413-421.